Effect of Personalized Risk-Reduction Strategies on Cognition and Dementia Risk Profile Among Older Adults
Yaffe, K, Vittinghoff, E, Dublin, S, Peltz, CB, Fleckenstein, LE, Rosenberg, DE, Barnes, DE, Balderson, BH, & Larson, EB (2024). Effect of Personalized Risk-Reduction Strategies on Cognition and Dementia Risk Profile Among Older Adults: The SMARRT Randomized Clinical Trial. JAMA internal medicine, 184(1), 54–62. https://doi.org/10.1001/jamainternmed.2023.627. PMID: 38010725; PMCID: PMC10682943.
Main Question
In older civillian adults, does a two-year, Systematic Multi-Domain Alzheimer Risk Reduction Trial (SMARRT) intervention improve cognition and reduce dementia risk?
Study Findings
Older adults randomized to SMARRT compared with the control group, had larger cognitive improvement, reduced dementia risk, and improved quality of life. Persons in SMARRT did not have an increased risk of serious adverse events but did have more individuals with treatment-related muskuloskeletal pain.
Practical Uses
The SMARRT intervention showed modest improvements in cognition, dementia risk factors, and quality of life.
Risk-reduction strategies such as SMARRT for modifiable factors should be considered for older adults at risk for dementia.
For more information on preventing dementia and early cognitive decline
In an effort to provide the latest findings to our consumers as quickly as possible, some of these studies, while fully peer reviewed, have not been presented or published either electronically or in print. Findings are presented for informational purposes only and should not be cited or referenced until they are formally published or presented.